Celator Pharmaceuticals, Inc. Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia  
1/26/2012 7:20:16 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced that the European Commission (EC) has granted orphan drug status to CPX-351, the company’s proprietary “liposomal combination of cytarabine and daunorubicin,” for the treatment of acute myeloid leukemia (AML). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA).